Merck Q2 2024 Earnings July 30, 2024 -- 1 of 31 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 31 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 31 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 31 -- Delivered on our key strategic priorities in Q2 2024 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to augment pipeline Created long-term value for patients and shareholders 5 -- 5 of 31 -- Drove innovation and productivity through integration of data, digital and analytics Reached more people globally with our medicines and vaccines Expanded and evolved our pipeline to drive future innovations for patients Significant progress over the past three years 6 -- 6 of 31 -- 20,000 30,000 40,000 50,000 60,000 70,000 2022 2023 2024 Strong Q2 sales1 and earnings performance 7 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude charges for certain upfront payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Second quarter of 2023 includes $4.02 per share of such charges. Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $0.77, $6.21 and $0.22 per share of such charges, respectively. 3. GAAP EPS $2.14. $16.1B +7% +11% ex-Exchange Q2 Worldwide Sales Q2 Non-GAAP EPS3 $5.37 Full Year Sales Full Year Non-GAAP EPS2 $59.3B +22% $60.1B +1% 2022 2023 2024 $1.51 $7.48 GUIDANCE RANGE $63.4B - $64.4B +5% - +7% GUIDANCE RANGE $7.94 - $8.04 $2.28 -- 7 of 31 -- Advancing our broad pipeline 8 Vaccines Cardiometabolic Oncology Successful initial launch following U.S. approval, and received positive CHMP opinion Recent FDA approval and unanimous ACIP recommendation in certain adult populations Diverse Portfolio & Pipeline Presented data for multiple novel candidates at ASCO -- 8 of 31 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 31 -- Strong Q2 worldwide sales growth 10 Merck WORLDWIDE SALES1,2 $16.1B+7% growth +11% ex-exchange3 $14.4B +7% growth +11% ex-exchange3 Human Health $1.5B +2% growth +6% ex-exchange3 Animal Health 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. ~2 percentage points of the negative impact of foreign exchange for Worldwide Sales and Human Health, and ~3 percentage points of the negative impact of foreign exchange for Animal Health, was due to devaluation of the Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 10 of 31 -- Oncology: KEYTRUDA continues to drive excellent growth 11 Growth rates exclude the impact of foreign exchange. 1. ~4 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. • KEYTRUDA sales of $7.3B increased 21%1 year-over-year, driven by uptake in earlier stage cancers and continued strong global demand from metastatic indications – In the U.S., increase reflects uptake from KN-671 and KN-091 in NSCLC, as well as uptake from KN-A39 in advanced urothelial cancer – Ex-U.S. growth reflects continued uptake in earlier stage cancers, including high-risk early- stage TNBC and adjuvant RCC, as well as demand from metastatic indications $4.2B +20% $3.4B +31% $5.3B +30% 2Q22 2Q23 2Q24 $5.3B +30% $6.3B +21% $7.3B +21% -- 11 of 31 -- Oncology: Strong performance across broad portfolio • Lynparza 1 sales grew 4%, driven primarily by higher demand in the U.S. and certain international markets • Lenvima 2 sales grew 4%, driven primarily by higher demand in the U.S. • WELIREG sales more than doubled, driven by increased uptake in certain patients with previously treated advanced RCC $181M +15% $151M +57% 12 Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 2Q22 2Q23 2Q24 $310M +15% $275M +17% $317M +4% 2Q22 2Q23 2Q24 $242M +6% $231M +33% $249M +4% 2Q22 2Q23 2Q24 $50M +89% $27M $126M +150% -- 12 of 31 -- 2Q22 2Q23 2Q24 $1.7B +40% 2Q22 2Q23 2Q24 $1.7B +40% $2.5B +53% Vaccines: Growth driven by GARDASIL and VAXNEUVANCE 13 • GARDASIL sales of $2.5B increased 4% year-over-year – In the U.S., sales benefitted from price, demand and favorable CDC purchasing patterns – Ex-U.S., sales were driven by higher demand across several markets, partially offset by timing of shipments in China • VAXNEUVANCE grew to $189M, driven by ongoing launches in ex-U.S. markets Growth rates exclude the impact of foreign exchange. $2.5B +4% $1.7B +40% $12M $168M $189M +16% -- 13 of 31 -- Cardiovascular: Successful initial launch of WINREVAIR 14 $1.7B +40% $1.9B +27% $2.5B +4% Sales of $70M1 Payors Prescribers Patients • Many payors established coverage policies consistent with the label and STELLAR criteria • Other payors are in the process of developing policies • >2,000 patients prescribed in the quarter • Across all prescriptions, ~75-80% of patients receive commercial product • >1,000 patients started treatment in the quarter, largely reflecting prescriptions written in April and May • Takes ~1 month on average for patients to start therapy • >500 physicians have written at least one prescription • Many prescribers are looking to gain experience with the product as they prioritize patients who are in greatest need of additional therapy • Most prescribers are from large academic centers or larger private practices 1. ~40% of sales were attributed to doses administered to patients, with the remainder due to distributors building inventory in support of increasing demand. -- 14 of 31 -- Animal Health: Growth driven by livestock 15 • Animal Health sales increased 6% 1 to $1.5B – Livestock sales grew 11%, driven by higher demand for poultry and ruminant products, as well as price – Companion Animal growth reflects price, partially offset by reduction in distributor inventory 2Q22 2Q23 2Q24 $1.5B +5% $1.5B +2% $1.5B +6% Growth rates exclude the impact of foreign exchange. 1. ~3 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 15 of 31 -- Q2 2024 non-GAAP financial results summary1 Q2 2024 Q2 2023 Change Change Ex-FX Sales $16.1 $15.0 +7% +11% Non-GAAP Gross Margin 80.9% 76.6% +4.3pts +4.3pts Non-GAAP Operating Expenses $6.2 $15.9 -61% -61% Non-GAAP Tax Rate 14.1% -18.4% +32.5pts N/A Non-GAAP Earnings / (Loss) Per Share2,3 $2.28 ($2.06) N/M N/M $ in billions, except EPS amounts 16 1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2023 includes a charge of $10.2 billion, or $4.02 negative EPS impact, for the acquisition of Prometheus Biosciences. 3. Q2 2024 GAAP EPS of $2.14. -- 16 of 31 -- Updated 2024 financial outlook 1. Guidance does not assume any additional significant potential business development transactions. 17 Prior Guidance Updated Guidance Key Assumptions Revenue $63.1B to $64.3B $63.4B to $64.4B • Assumes ~3 percentage point FX headwind • Implies growth of 5% to 7% Non-GAAP Gross Margin Rate ~81.0% ~81.0% Non-GAAP Operating Expenses1 $25.2B to $26.1B $26.8B to $27.6B • Includes incremental $1.5B of charges related to EyeBio acquisition and advancing assets, as well as investments in progressing innovative pipeline Other (Income) / Expense ~$250M of expense ~$350M of expense • Includes financing costs for the acquisitions of EyeBio and Elanco’s aqua business Tax Rate ~14.5% to 15.5% ~15.5% to 16.5% • Includes unfavorable impact from the non-tax deductible upfront charge related to acquisition of EyeBio Shares Outstanding ~2.55B ~2.54B • Assumes modest share repurchase Non-GAAP EPS $8.53 to $8.65 $7.94 to $8.04 • Includes one-time ~$0.51 charge related to EyeBio acquisition, as well as ~$0.09 to finance EyeBio and Elanco aqua business acquisitions and advance the acquired assets • Assumes more than $0.30 FX headwind in 2024 -- 17 of 31 -- Key modeling considerations CAPVAXIVE GARDASIL • Received FDA approval and ACIP recommendation • Commercial uptake will be enabled by milestones such as MMWR publication, which typically lags ACIP recommendation by a few months, as well as payor coverage and customer contracting 18 • Benefitted from extremely strong demand of GARDASIL in China over the past few years • In 2Q there was a significant step down in shipments from Zhifei to points of vaccination compared to prior quarters, resulting in higher inventory levels at Zhifei • If shipments from Zhifei do not increase, it is likely that we will ship less than our full year 2024 contracted doses1 by the end of this year • Opportunity in China remains very attractive as there are >120M females in the addressable population living in Tier 1-5 cities have not yet received an HPV vaccination WINREVAIR • Received CHMP opinion and anticipate EMA approval in the coming months • Reimbursement should occur in 2025 in most major markets, but expect Germany will receive reimbursement and launch this year 1. Contracted doses in 2024 are less than the doses that were shipped in 2023 -- 18 of 31 -- 19 Continue to invest in the pipeline and business while augmenting the pipeline with value-enhancing business development $3.0 $0.7 $2.0 $0.2 $0.3 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Q2 Spend ($ in billions) 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Remain committed to balanced capital allocation strategy Capital allocation order of priority 2 -- 19 of 31 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 20 of 31 -- Important progress across our immunization programs 21 Pneumococcal RSV • Received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine for adults, as well as unanimous ACIP recommendation for certain adult populations • First approved pneumococcal conjugate vaccine specifically designed to cover serotypes responsible for ~85% of incidence of invasive pneumococcal disease in individuals 65 years and older 1 • Currently under review by EMA • Announced positive topline results from Phase 2b/3 trial evaluating clesrovimab, an investigational RSV preventative monoclonal antibody for infants • Study met primary efficacy and safety endpoints, as well as secondary endpoint regarding RSV-associated hospitalization • Potential to provide a single, fixed-dose option to help protect healthy and high-risk infants from birth through their first full RSV season 1. According to CDC data from 2018-2021 -- 21 of 31 -- Executing upon our oncology development strategy 22 Immuno-oncology Boost anti-tumor immune responses Precision Molecular Targeting Impact pathways that can drive cancer growth Tissue Targeting Increase cancer cell sensitivity with ADCs and immune- engagers -- 22 of 31 -- Continuing to harness the power of immuno-oncology 23 Recent KEYTRUDA Updates • KEYNOTE-868: FDA approved KEYTRUDA in combination with chemotherapy for treatment of primary advanced or recurrent endometrial cancer regardless of mismatch repair status • KEYNOTE-522: Announced study demonstrated OS benefit in patients with high-risk early-stage TNBC • KEYNOTE-811: Announced study met OS dual primary endpoint for treatment of 1L HER2-positive advanced gastric or GEJ adenocarcinoma • KEYNOTE-483: FDA granted priority review for KEYTRUDA in combination with chemotherapy for 1L treatment of unresectable advanced or metastatic malignant pleural mesothelioma (PDUFA September 25, 2024) Total: 40 approvals1 in distinct indications 25 studies with OS benefit Earlier Stage: 9 approvals1 in distinct indications 4 studies with OS benefit 1. Represents approvals in the U.S. -- 23 of 31 -- 24 Updates across precision and tissue targeting Precision Molecular Targeting Tissue Targeting • Exercised option to advance opevesostat1 , an oral nonsteroidal CYP11A1 inhibitor • Two ongoing Phase 3 trials, OMAHA-1 and OMAHA-2, evaluating opevesostat1 in combination with hormone replacement therapy for treatment of certain patients with metastatic prostate cancer • Received positive CHMP opinion for KEYTRUDA in combination with Padcev for 1L treatment of patients with unresectable or metastatic urothelial carcinoma based on KN-A39/EV-3022 • FDA issued a Complete Response Letter for BLA for patritumab deruxtecan3 for treatment of certain adult patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with two or more systemic therapies 1. In collaboration with Orion 2. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 3. In collaboration with Daiichi Sankyo -- 24 of 31 -- Ophthalmology • Completed acquisition of EyeBio • Restoret /MK-3000 is an investigational, potentially first-in-class tetravalent tri-specific Wnt antibody for treatment of diabetic macular edema and neovascular age-related macular degeneration 25 Important developments across our diverse pipeline Cardiometabolic • Received positive CHMP opinion for WINREVAIR for treatment of PAH • Anticipate European Commission decision on marketing authorization application in 3Q 2024 Restoret /MK-30001: -- 25 of 31 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Senior Vice President, Investor Relations -- 26 of 31 -- Appendix 27 -- 27 of 31 -- Q2 2024 GAAP financial results summary 28 Q2 2024 Q2 2023 Change Change Ex-FX Sales $16.1 $15.0 +7% +11% Operating Expenses1 $6.2 $16.0 -61% -60% Tax Rate 9.1% -11.9% -21.0pts N/A GAAP Earnings / (Loss) per Share1 $2.14 ($2.35) N/M N/M $ in billions, EPS amounts 1. 2Q23 GAAP results include $10.2 billion charge or $4.02 per share for the acquisition of Prometheus Biosciences -- 28 of 31 -- $11.4 $3.5 $7.6 $7.0 $1.2 $0 $3 $6 $9 $12 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 19B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$11B in the U.S. Billions Over the past 12 months Capital investments 2024 to 2028 Commitment to the dividend 29 Well-positioned balance sheet with capacity to fund additional value-enhancing business development opportunities Order of priority 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow 3. Updated October 29, 2024: Previous values corrected by the company 2 1 E -- 29 of 31 -- Driving value for patients and shareholders by progressing our pipeline Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S.: o FDA accepted for priority review the sBLA for KEYTRUDA in combination with chemotherapy as first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma based on IND.227/KN-483 o FDA approved KEYTRUDA in combination with chemotherapy, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma based on NRG- GY018/KN-868 o FDA approved CAPVAXIVE for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults, and CDC’s ACIP unanimously voted to recommend CAPVAXIVE as an option for certain adults • In the EU: o Received positive CHMP opinion for KEYTRUDA in combination with Padcev for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma based on KN-A39/EV-302 1 o Received positive CHMP opinion for WINREVAIR, in combination with other PAH therapies, for the treatment of PAH in adult patients with WHO FC II to III • Presented data across broad oncology portfolio at ASCO, including for KEYTRUDA (KN-966, KN-859, KN-A39, KN-671, KN-224, KN-629), mRNA-4157/V940 2 (INT), vibostolimab (anti-TIGIT), sacituzumab tirumotecan 3 (TROP2 ADC), and patritumab deruxtecan 4 (HER3 ADC) • Announced Phase 2b/3 trial evaluating clesrovimab (MK-1654) met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150 • Announced Phase 3 KEYNOTE-811 and KEYNOTE-522 trials for KEYTRUDA met overall survival endpoints • Advanced our broad pipeline, initiating Phase 3 trials across multiple candidates including sacituzumab tirumotecan 3 (MK- 2870, TROP2 ADC), enlicitide decanoate (MK-0616, PCSK9 inhibitor), and tulisokibart (MK-7240, TL1A inhibitor) 30 1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. In collaboration with Moderna 3. In collaboration with Kelun-Biotech 4. In collaboration with Daiichi Sankyo -- 30 of 31 -- Broad and innovative pipeline to address significant unmet medical needs Phase 2 Phase 3 Under regulatory review V181 Dengue Virus Vaccines Infectious disease MK-8189 4 Schizophrenia Neuroscience MK-8527 HIV-1 prevention MK-8591B (islatravir+MK-8507)1 HIV-1 infection MK-8591D (islatravir+lenacapavir)2,11 HIV-1 infection MK-2060 Thrombosis MK-5475 PH-COPD MK-6024 (efinopegdutide) NASH WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic MK-4280A (favezelimab+pembroliz umab) Bladder cSCC Endometrial Esophageal Melanoma RCC MK-5890 (boserolimab) Neoplasm Malignant MK-5909 (raludotatug deruxtecan)6 Ovarian LYNPARZA (MK-7339)8 Advanced Solid Tumors LENVIMA (MK-7902)9 HNSCC MK-2870 (sacituzumab tirumotecan)7 Biliary CRC Neoplasm Malignant Pancreatic KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-3475A (pembrolizumab + hyaluronidase) cSCC MK-4280 (favezelimab) NSCLC WELIREG (MK-6482) Endometrial Esophageal HCC Prostate Rare Cancers MK-7684A (vibostolimab +pembrolizumab) Bladder CRC Endometrial Melanoma Ovarian Prostate RCC V940 10 Bladder cSCC RCC MK-1022 (patritumab deruxtecan)6 Gastric HNSCC Melanoma MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan)6 Bladder CRC Endometrial HNSCC 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023 6 In collaboration with Daiichi Sankyo 7In collaboration with Kelun-Biotech 8 In collaboration with AstraZeneca 9 In collaboration with Eisai 10In collaboration with Moderna 11In collaboration with Gilead 12Developed under an agreement with Ridgeback Bio 13 In collaboration with Orion 14 FDA issued CRL in June 2024 MK-6194 Vitiligo Immunology Restoret /MK-3000 Diabetic macular edema Ophthalmology Oncology Infectious disease Oncology MK-1022 (patritumab deruxtecan)6 NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 NSCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-2400 (ifinatamab deruxtecan)6 SCLC MK-2870 (sacituzumab tirumotecan)7 Breast Cervical Gastric Endometrial NSCLC MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) CSCC (EU) Hepatocellular (EU) Ovarian SCLC MK-3475A (pembrolizumab +hyaluronidase) NSCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies MK-5684 (opevesostat)13 Prostate LYNPARZA (MK-7339)8 NSCLC SCLC LENVIMA (MK-7902)9 Esophageal Gastric MK-7684A (vibostolimab +pembrolizumab) NSCLC SCLC V940 10 Melanoma NSCLC MK-8591A (doravirine+islatravir)2 HIV-1 Infection Immunization MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) Cardiometabolic MK-7240 (tulisokibart) Ulcerative Colitis Immunology MK-0616 (enlicitide decanoate) Hypercholesterolemia LAGEVRIO (MK-4482)3,12 COVID-19 antiviral Gefapixant (MK-7264)5 Cough (US) General Medicine As of July 30, 2024 Oncology KEYTRUDA (MK-3475) Resectable NSCLC (JPN) 1L Urothelial (EU, JPN) Endometrial Carcinoma (EU, JPN) Cervical (EU, JPN) Mesothelioma (US, EU, JPN) MK-1022 (patritumab deruxtecan)6, 14 NSCLC (US) WELIREG (MK-6482) Certain VHL tumors (EU) Advanced RCC (EU, JPN) WINREVAIR (MK-7962) Pulmonary Arterial Hypertension (EU) Cardiometabolic Vaccines CAPVAXIVE (V116) Pneumococcal conjugate vaccine, adult (EU) -- 31 of 31 --